Market Closed -
Nasdaq
16:00:00 2026-07-23 EDT
5-day change
1st Jan Change
104.79 USD
+1.98%
+9.90%
+836.16%
Market Cap
42.24M
37.15M
34.51M
31.74M
59.53M
4.09B
60.6M
413M
161M
2B
159M
155M
6.92B
P/E 2021
-3.42x
P/E 2022
-0.31x Enterprise Value
-39.84M
-35.04M
-32.55M
-29.93M
-56.14M
-3.86B
-57.14M
-389M
-152M
-1.88B
-150M
-146M
-6.53B
EV / Sales 2021
-
EV / Sales 2022
-
Free-Float
-
Yield 2021 *
-
Yield 2022
-
5 minutes 15 minutes 30 minutes Hour Day Week Month
Candlestick Close OHLC Mountain
Nasdaq
Deutsche Boerse AG
23-09-11
Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index
CI
23-09-10
Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.
CI
23-08-03
Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
23-06-23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index
CI
23-06-23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index
CI
23-06-23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index
CI
23-06-23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index
CI
23-05-19
Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer
CI
23-05-15
Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
23-05-03
Dianthus Therapeutics, Inc., Magenta Therapeutics, Inc. - M&A Call
23-05-02
Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction.
CI
23-04-06
Magenta Therapeutics, Inc. Enters into Sublease Termination and Release Agreement with Novartis Institutes for Biomedical Research, Inc
CI
23-02-28
HC Wainwright Initiates Magenta Therapeutics at Neutral
MT
23-09-11
Adrenoleukodystrophy Clinical Trials, and Key Companies|Companies - Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others
AQ
23-08-07
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
BU
23-05-03
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
BU
23-05-03
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
23-05-03
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
AQ
1 day +1.98%
Current month +836.16%
Current year +836.16%
3 years
10.9
106.56
5 years
5.14
135.84
10 years
5.14
336
2021 2022 Net sales
-
-
Net income
-71.14M
-62.56M
-58.12M
-53.46M
-100M
-6.89B
-102M
-695M
-271M
-3.36B
-267M
-261M
-11.66B
-76.46M
-67.25M
-62.47M
-57.46M
-108M
-7.4B
-110M
-747M
-291M
-3.61B
-287M
-281M
-12.53B
Net Debt
-177M
-156M
-145M
-133M
-249M
-17.13B
-254M
-1.73B
-674M
-8.36B
-664M
-650M
-28.99B
-82.08M
-72.19M
-67.06M
-61.68M
-116M
-7.95B
-118M
-802M
-313M
-3.88B
-308M
-301M
-13.45B
Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Date
Price
Change
Volume
26-07-23
US$104.79
+1.98%
884,008
26-07-22
US$102.76
-2.80%
1,028,674
26-07-21
US$105.72
+4.67%
621,403
26-07-20
US$101.00
-4.36%
837,670
26-07-17
US$105.60
+10.75%
1,025,195
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-6pm CET
DAILY FREE LIMIT REACHED
To continue browsing, Sign up!
Personal watchlists and screeners
Access the "Discovery" Stock Screener (covering 30,000 companies)
Create your free account
Become a member and join over 1 million active investors
Are you already registered?
Log in
Select your edition
All financial news and data tailored to specific country editions
